- Home
- FENC vs RNA Comparison
FENC vs RNA Comparison
Compare FENC & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FENC | RNA |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.8M | 222.5M |
| IPO Year | 2010 | 2025 |
Fundamental Metrics
Financial Performance| Metric | FENC | RNA |
|---|---|---|
| Price | $11.57 | $12.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 20 |
| Target Price | $14.50 | ★ $69.26 |
| AVG Volume (30 Days) | 127.4K | ★ 127.8K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $44,642,000.00 | N/A |
| Revenue This Year | $65.12 | $88.12 |
| Revenue Next Year | $41.08 | $18.11 |
| P/E Ratio | $1,084.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.65 | $11.13 |
| 52 Week High | $11.31 | $73.06 |
Technical Indicators
Market Signals| Indicator | FENC | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 60.06 | 51.20 |
| Support Level | $9.91 | $11.95 |
| Resistance Level | $11.28 | $14.05 |
| Average True Range (ATR) | 0.60 | 0.39 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 92.92 | 80.33 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.